Eliminating biofilm from ureteral stents: The holy grail

Current Opinion in Urology

Volumn 19, Issue 2, 2009, Pages 205-210

  Denstedt, John D ^a,c,d   Cadieux, Peter A ^a,b,c  

^a Division of Urology   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Biofilm; Ureteral stent; Urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; ANTIFOULING AGENT; ANTIINFECTIVE AGENT; CHLORHEXIDINE; DOPA; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); EPIGALLOCATECHIN GALLATE; HEPARIN; MACROGOL; PROTAMINE SULFATE; SILVER; TEICOPLANIN; TRICLOSAN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; BIOFILM; CLINICAL TRIAL; DEVICE INFECTION; DRUG ELUTING STENT; DRUG POTENTIATION; HUMAN; HYDROGEL; LONG TERM CARE; MATERIAL COATING; MICROBIAL COLONIZATION; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; URETER OBSTRUCTION; URETER STENT; URETHRAL CATHETER; URINARY TRACT INFECTION; URINE CULTURE;

ANIMALS; BIOFILMS; HUMANS; STENTS; URINARY CATHETERIZATION;

EID: 61349204549     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328323d6d2     Document Type: Review

References (59)

1. Chew BH, Duvdevani M, Denstedt JD. New developments in ureteral stent design, materials and coatings. Expert Rev Med Devices 2006; 3:395-403.
2. Reid G, Denstedt JD, Kang YS, et al. Microbial adhesion and biofilm formation on ureteral stents in vitro and in vivo. J Urol 1992; 148:1592-1594.
3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:3.
4. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev 2007; 5:48-56.
5. Slawson RM, Van Dyke Ml, Lee H, Trevors JT. Germanium and silver resistance, accumulation, and toxicity in microorganisms. Plasmid 1992; 27:72-79.
6. Davenport K, Keeley FX. Evidence for the use of silver-alloy-coated urethral catheters. J Hosp Infect 2005; 60:298-303.
7. Bjarnsholt T, Kirketerp-Moller K, Kristiansen S, et al. Silver against Pseudomonas aeruginosa biofilms. APMIS 2007; 115:921-928.
8. Roe D, Karandikar B, Bonn-Savage N, et al. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemother 2008; 61:869-876. Nanoparticle technology is used to apply silver to the surface of catheter material, which can also be applied to ureteral stents. The article highlights the ability to use nanoparticles to deliver compounds in sufficient quantities for controlled therapeutic use.
9. Yao Y, Ohko Y, Sekiguchi Y, et al. Self-sterilization using silicone catheters coated with Ag and TIO2 nanocomposite thin film. J Biomed Mater Res B Appl Biomater 2008; 85:453-460.
10. Bhargava HN, Leonard PA. Triclosan: applications and safety. Am J Infect Control 1996; 24:209-218.
11. Heath RJ, White SW, Rock CO. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl Microbiol Biotechnol 2002; 58:695-703.
12. Heath RJ, Yu YT, Shapiro MA, et al. Broad spectrum antimicrobial biocides target the Fabl component of fatty acid synthesis. J Biol Chem 1998; 273:30316-30320.
13. Chew BH, Cadieux PA, Reid G, Denstedt JD. In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens. J Endourol 2006; 20:949-958.
14. Cadieux PA, Chew BH, Knudsen BE, et al. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006; 175:2331-2335.
15. Elwood CN, Chew BH, Seney S, et al. Triclosan inhibits uropathogenic Escherichia coli-stimulated tumor necrosis factor-alpha secretion in T24 bladder cells in vitro. J Endourol 2007; 21:1217-1222.
16. Cadieux PA, Chew BH, Nott L, et al. The use of triclosan-eluting ureteral stents in long-term stented patients. J Endourol 2008.
17. Wignall GR, Goneau LW, Chew BH, et al. The effects of triclosan on uropathogen susceptibility to clinically relevant antibiotics. J Endourol 2008; 22:2349-2356.
18. Jones GL, Muller CT, O'Reilly M, Stickler DJ. Effect of triclosan on the development of bacterial biofilms by urinary tract pathogens on urinary catheters. J Antimicrob Chemother 2006; 57:266-272.
19. Jones GL, Russell AD, Caliskan Z, Stickler DJ. A strategy for the control of catheter blockage by crystalline Proteus mirabilis biofilm using the antibacterial agent triclosan. Eur Urol 2005; 48:838-845.
20. Williams GJ, Stickler DJ. Effect of triclosan on the formation of crystalline biofilms by mixed communities of urinary tract pathogens on urinary catheters. J Med Microbiol 2008; 57 (Pt 9):1135-1140.
21. Williams GJ, Stickler DJ. Some observations on the diffusion of antimicrobial agents through the retention balloons of foley catheters. J Urol 2007; 178:697-701. Placement of triclosan and other antimicrobial compounds in the retention balloons of Foley catheters prevented attachment, survival and biofilm formation of multiple uropathogens on the devices. This work highlights the use of retention balloons as a means to deliver compounds to the urinary tract.
22. Stickler DJ, Jones GL. Reduced susceptibility of Proteus mirabilis to triclosan. Antimicrob Agents Chemother 2008; 52:991-994.
23. Chosa H, Toda M, Okubo S, et al. Antimicrobial and microbicidal activities of tea and catechins against Mycoplasma. Kansenshogaku Zassh 1992; 66:606-611.
24. Sudano Roccaro A, Blanco AR, Giuliano F, et al. Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob Agents Chemother 2004; 48:1968-1973.
25. Gradisar H, Pristovsek P, Plaper A, Jerala R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem 2007; 50:264-271.
26. Blanco AR, Sudano-Roccaro A, Spoto GC, et al. Epigallocatechin gallate inhibits biofilm formation by ocular staphylococcal isolates. Antimicrob Agents Chemother 2005; 49:4339-4343.
27. Maeyama R, Kwon I, Mizunoe Y, et al. Novel bactericidal surface: catechin-loaded surface-erodible polymer prevents biofilm formation. J Biomed Mater Res A 2005; 75A:146-155.
28. Peng G, Wargovich MJ, Dixon DA. Antiproliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Lett 2006; 238:260-270.
29. Tipoe GL, Leung TM, Hung MW, Fung ML. Green tea polyphenols as an antioxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Hematol Disord Drug Targets 2007; 7:135-144.
30. Cho HH, Han DW, Matsumura K, et al. The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-epsilon-caprolactone) as stent-coating materials. Biomaterials 2008; 29:884-893. EGCg compound is not only antimicrobial and prevented biofilm formation but has strong anti-inflammatory and antiproliferative effects on the host. This compound may prove important for ureteral stent use not only as an antibacterial coating but also in controlling ureteral healing and preventing inflammation associated with stent use.
31. DiTizio V, Ferguson GW, Mittelman MW, et al. A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials 1998; 19:1877-1884.
32. Nablo BJ, Prichard HL, Butler RD, et al. Inhibition of implant-associated infections via nitric oxide release. Biomaterials 2005; 26:6984-6990.
33. Pugach JL, DiTizio V, Mittelman MW, et al. Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. J Urol 1999; 162 (3 Pt 1):883-887.
34. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Efficacy of combination of chlorhexidine and protamine sulphate against device-associated pathogens. J Antimicrob Chemother 2008; 61:651-657. Use of antibiotics in conjunction with protamine sulfate to reduce bacterial attachment, survival and biofilm formation on urinary tract device materials. The study supports the use of antimicrobial compounds in wetting hydrogels to further prevent device-associated infections.
35. John T, Rajpurkar A, Smith G, et al. Antibiotic pretreatment of hydrogel ureteral stent. J Endourol 2007; 21:1211-1215.
36. Laube N, Kleinen L, Bradenahl J, Meissner A. Diamond-like carbon coatings on ureteral stents: a new strategy for decreasing the formation of crystalline bacterial biofilms? J Urol 2007; 177:1923-1927. Novel diamond-like carbon coating exhibited decreased crystalline biofilm formation. Further research is needed, but the novel strategy is of interest.
37. Liu C, Zhao Q, Liu Y, et al. Reduction of bacterial adhesion on modified DLC coatings. Colloids Surf B Biointerfaces 2008; 61:182-187.
38. Morra M. On the molecular basis of fouling resistance. J Biomater Sci Polym Ed 2000; 11:547-569.
39. Dalsin JL, Lin L, Tosatti S, et al. Protein resistance of titanium oxide surfaces modified by biologically inspired mPEG-DOPA. Langmuir 2005; 21:640-646.
40. Waite JH, Tanzer ML. The bioadhesive of Mytilus byssus: a protein containing L-dopa. Biochem Biophys Res Commun 1980; 96:1554-1561.
41. Ko R, Cadieux PA, Dalsin JL, et al. First prize: novel uropathogen-resistant coatings inspired by marine mussels. J Endourol 2008; 22:1153-1160. Strong inhibition of urinary constituent and uropathogen attachment, as well as biofilm formation, using polyethylene-glycol-based coatings over 24 h in a urine environment. Coatings were attached using a component derived from marine mussel adhesives.
42. Pechey A, Elwood CN, Wignall GR, et al. Effects of novel coatings inspired by marine mussels on ureteral stent encrustation and uropathogen adherence in vivo. Submitted J Urol 2008.
43. Rose SF, Okere S, Hanlon GW, et al. Bacterial adhesion to phosphorylcholine-based polymers with varying cationic charge and the effect of heparin preadsorption. J Mater Sci Mater Med 2005; 16:1003-1015.
44. Tenke P, Riedl CR, Jones GL, et al. Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. Int J Antimicrob Agents 2004; 23 (Suppl 1):S67-74.
45. Cauda F, Cauda V, Fiori C, et al. Heparin coating on ureteral double J stents prevents encrustations: an in vivo case study. J Endourol 2008; 22:465-472.
46. Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:4596-4606.
47. Shanks RM, Sargent JL, Martinez RM, et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21:2247-2255.
48. Frank KL, Patel R. Intravenously administered pharmaceuticals impact biofilm formation and detachment of Staphylococcus lugdunensis and other staphylococci. Diagn Microbiol Infect Dis 2008; 60:9-16. Intravenously administered heparin prevented the formation of detached biofilms of staphylococci from venous catheter material. The study highlights the ability to use systemic compounds to remove existing biofilms as well as prevent their formation.
49. Haile DT, Hughes J, Vetter E, et al. Frequency of isolation of Staphylococcus lugdunensis in consecutive urine cultures and relationship to urinary tract infection. J Clin Microbiol 2002; 40:654-656.
50. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev 2008; 6:17-27. Good review concerning the future of antibacterial therapies with regard to biofilms and infection. The review deals largely with urological infections and strategies.
51. Opal SM. Communal living by bacteria and the pathogenesis of urinary tract infections. PLoS Med 2007; 4:e349. Solid review on biofilms in general and their association with infections of the urinary tract. It discusses biomaterial-associated infections as well as recurrent infections caused by intracellular biofilms formed in urothelial cells.
52. Bjarnsholt T, Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem 2007; 387:409-414.
53. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as antipathogenic drugs. Int J Med Microbiol 2006; 296:149-161.
54. Laux DC, Corson JM, Givskov M, et al. Lysophosphatidic acid inhibition of the accumulation of Pseudomonas aeruginosa PAO1 alginate, pyoverdin, elastase and LasA. Microbiology 2002; 148 (Pt 6):1709-1723.
55. Hentzer M, Riedel K, Rasmussen TB, et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002; 148 (Pt 1):87-102.
56. Balaban N, Stoodley P, Fux CA, et al. Prevention of staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP. Clin Orthop Relat Res 2005:48-54.
57. Dell'Acqua G, Giacometti A, Cirioni O, et al. Suppression of drug-resistant staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis 2004; 190:318-320.
58. Cirioni O, Ghiselli R, Minardi D, et al. RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection. Antimicrob Agents Chemother 2007; 51:4518-4520. RNAIII-inhibiting peptide was found to work in strong conjunction with teicoplanin to virtually eliminate S. aureus biofilm formation from ureteral stent material in a rat bladder model.
59. Kiran MD, Adikesavan NV, Cirioni O, et al. Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening. Mol Pharmacol 2008; 73:1578-1586. Hamamelitannin was discovered as a nonpeptide-based analog to the quorum-sensing inhibitor, RIP. Using a virtual screening tool to discover novel therapeutical compounds is very promising for not only inhibiting biofilm formation but also medicine in general.